Share this article and save a life!
97% vs 50%. That’s AI beating radiologists at finding pancreatic cancer.
Mayo Clinic just announced something extraordinary.
Their new AI model detects pancreatic cancer 438-475 days BEFORE clinical diagnosis. That’s over a year of lead time for a cancer that typically kills within months.
The numbers are staggering:
• AI detection rate: 97%
• Radiologist detection rate: 50%
• Overall accuracy: 92%
• Analysis time: Under 1 second (vs 20-30 minutes manually)
Why this matters 🎯
Pancreatic cancer has a 13% five-year survival rate. Half of all cases are diagnosed at stage four, when it’s already too late.
But catch it early? The survival rate jumps to 44%.
That’s a 3X improvement in survival odds.
The AI was trained on over 3,000 patients and analyzed more than a million cancer slides. It remained accurate across diverse patient groups and different scanning equipment.
Here’s what strikes me most:
We’re not talking about experimental technology anymore. Mayo is already moving this through clinical validation and regulatory approval. They’re preparing screening trials for high-risk populations.
This could fundamentally change how we approach one of medicine’s most challenging cancers.
Think about it: Every patient with a family history of pancreatic cancer, every diabetic getting routine CT scans, every person with chronic pancreatitis could benefit from this screening.
The technology exists. The accuracy is proven. Now it’s about implementation.
How quickly can we get this into every radiology department? How do we ensure equitable access? Who decides which patients get screened?
These are the questions that will determine whether this breakthrough saves thousands of lives or becomes another innovation limited to major medical centers.
What’s your take on AI screening implementation in your organization?
♻️ Repost if early cancer detection should be standard care for high-risk patients.
👉 Follow me, Jonathan Govette, for daily, real-time updates on healthcare technology and business news. LinkedIn Profile: https://www.linkedin.com/in/jonathangovette/
Share this article and save a life!
Author:
CEO/Co-Founder @ Oatmeal Health | AI Lung Cancer Screening | Almost Became a Doctor | Engineer | Follow to Share What I’ve Learned Along the Way
I help patients get the care they need earlier, preventing late-stage cancer.
That’s been the throughline across three companies and almost 20 years in healthcare. At ReferralMD, we fixed broken referral networks so patients didn’t fall through the cracks. At Oatmeal Health, it’s lung cancer: building the diagnostic and screening infrastructure so the 85% of cases caught too late get caught early instead.
Today as CEO of Oatmeal Health, I lead a team embedding AI into radiology workflows to turn routine lung CT scans into reimbursable cancer risk assessments. We partner with FQHCs to reach underserved communities, and with health systems and payers to make early detection economically sustainable. Think HeartFlow or Cleerly, but for lungs.
Between companies, I advised at Techstars and Plug and Play, mentoring founders building in digital health. That experience shaped how I think about what separates companies that ship from companies that stall: distribution, reimbursement, and clinical trust, not just technology.
I’m a CancerX alumnus, a 3x healthcare founder, and someone who believes the biggest problems in cancer aren’t scientific. They’re operational.
We’re hiring mission-driven builders at Oatmeal Health. If you want to work on something that matters, reach out.
When I’m not working, I’m traveling, mentoring, and keeping up with one very energetic husky. 🐾
Substack – The Oatmeal Bite:
Millions of patients get less care because of who they are, where they live, or how they look. I’m fighting to change that. CEO @OatmealHealth, a startup built for the underserved. The Oatmeal Bite: intel for clinicians, investors, and advocates.
Jonathan Govette
CEO of Oatmeal Health
Substack:
https://oatmealhealthjonathangovette.substack.com/
